CD7 and T-cell acute lymphoblastic leukemia: In T-cell acute lymphoblastic leukemia (T-ALL), frameshift or missense mutations in exons one to three of CD7 were associated with antigen-negative relapse following anti-CD7 CAR-T therapy [5].